Matrifen

Fentanyl, the active ingredient in Matrifen, is an opioid analgesic presented as a transdermal patch for transdermal use. It is indicated for the management of severe chronic pain and cancer‑related pain in patients who require continuous opioid therapy.

GNH USA supplies Matrifen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company follows EU regulatory standards and offers reliable sourcing for healthcare providers across multiple regions. All batches are manufactured under GMP conditions and undergo rigorous quality testing before release.

Fentanyl transdermal patches provide continuous opioid delivery for conditions involving severe persistent pain. - Severe chronic pain: Provides long‑acting analgesia to maintain stable pain control in opioid‑tolerant patients. - Cancer‑related pain: Delivers consistent opioid levels to manage pain associated with malignant disease. - Post‑operative pain requiring prolonged opioid therapy: Offers an alternative to oral opioids for patients needing extended analgesia after surgery.

Transdermal fentanyl may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate feeling of sickness. - Constipation: reduced bowel movements. - Dizziness: light‑headed sensation. - Skin irritation at patch site: redness or itching.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing that can be life‑threatening. - Severe hypotension: marked drop in blood pressure. - Opioid dependence or withdrawal: signs of addiction or withdrawal upon discontinuation.

When prescribing Matrifen, clinicians should observe several safety precautions to minimize risk. - Assess opioid tolerance: confirm patient is opioid‑tolerant before initiating therapy. - Evaluate respiratory status: avoid use in patients with compromised ventilation. - Monitor for signs of abuse: implement regular assessments for misuse. - Adjust for hepatic impairment: use lower doses or increased monitoring in liver disease. - Avoid concurrent CNS depressants: limit use with benzodiazepines or alcohol. - Store at room temperature: keep patches below 25 °C in original packaging, protected from moisture and light.

Fentanyl interacts with several drug classes, requiring careful management to prevent adverse outcomes.

Major Interactions (Avoid): - Concurrent use with other opioids: may cause additive respiratory depression. - Benzodiazepines or barbiturates: increase risk of profound sedation and respiratory compromise. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise fentanyl plasma levels leading to toxicity.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy by lowering plasma concentrations. - MAO inhibitors: can potentiate opioid effects and cause hypertension. - Alcohol: enhances central nervous system depression.